SEC Form 4 · accession 0001104659-26-075773
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Angelos M. Stergiou
Officer — President and CEO · Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 16, 2026 | A | 1,065,000 | $0.00 | A | 1,759,183 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.